Valuation: HighTide Therapeutics, Inc.

Market Cap 1.28B 1.49B 189M 165M 153M 141M 266M 18.08B 270M 1.81B 709M 9B 711M 696M 30.19B P/E 2024
-1.41x
P/E 2025 -5.19x
Enterprise Value 904M 1.05B 134M 116M 108M 99.38M 188M 12.77B 191M 1.28B 501M 6.36B 502M 491M 21.32B EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
44.17%
Yield 2024 *
-
Yield 2025 -
1 day+4.00%
1 week-1.89%
1 month-2.99%
3 months-32.29%
6 months-2.99%
Current year-11.86%
1 week 2.47
Extreme 2.47
2.68
1 month 2.32
Extreme 2.32
3.01
Current year 1.8
Extreme 1.8
4.72
1 year 1.8
Extreme 1.8
4.72
3 years 0.72
Extreme 0.72
13.18
5 years 0.72
Extreme 0.72
13.18
10 years 0.72
Extreme 0.72
13.18
Manager TitleAgeSince
Chief Executive Officer 56 01/01/2011
Director of Finance/CFO 57 01/12/2022
Chief Tech/Sci/R&D Officer - 02/02/2026
Director TitleAgeSince
Chairman 56 -
Director/Board Member 44 15/05/2023
Director/Board Member 68 30/11/2020
Date Insider Type Main position Quantity % Market Cap.
30/4/26 Other

Director

1,800,000 0.3151%
1/4/25 Other

Chief Executive Officer

3,960,550 0.7694%
1/1/25 Other

Chief Executive Officer

2,789,803 0.5420%
Change 5-day change 1-year change 3-year change Capi.($)
+4.00%-1.89%-20.97% - 189M
+2.35%+2.74%+33.41%+79.20% 56.54B
-0.21%-7.38%+25.34%+63.02% 53.6B
-2.44%+1.40%-15.74%-16.80% 22.91B
-2.85%-7.78%-8.09%+346.36% 21.37B
+2.49%-0.92%+20.31%-12.15% 20.27B
+0.79%-1.06%+29.29%-33.32% 17.56B
+0.58%-5.88%+16.30%+540.37% 14.75B
-5.25%-4.23%+46.41%+169.05% 13.33B
+3.41%-6.61%+163.08%+280.43% 13.53B
Average +0.29%-3.60%+28.93%+157.35% 23.4B
Weighted average by Cap. +0.23%-2.96%+28.63%+119.98%

Financials

2024 2025
Net sales - -
Net income -382M -443M -56.52M -49.13M -45.73M -41.99M -79.29M -5.4B -80.52M -539M -212M -2.69B -212M -208M -9.01B -245M -284M -36.27M -31.53M -29.34M -26.94M -50.88M -3.46B -51.66M -346M -136M -1.72B -136M -133M -5.78B
Net Debt -413M -479M -61.11M -53.12M -49.45M -45.4M -85.73M -5.83B -87.06M -583M -229M -2.9B -230M -224M -9.74B -376M -436M -55.66M -48.38M -45.03M -41.35M -78.08M -5.31B -79.29M -531M -208M -2.65B -209M -204M -8.87B
Logo HighTide Therapeutics, Inc.
HighTide Therapeutics Inc is a biopharmaceutical company specializing in the discovery, development and commercialization of multifunctional, multi-targeted therapies for the treatment of metabolic and digestive diseases. The Company has developed a product pipeline of multiple product candidates in-house, covering many indications in metabolic and digestive diseases among which, some are at clinical-stage. The Company’s core product, HTD1801 (berberine ursodeoxycholate), a new molecular entity, is a gut-liver anti-inflammatory metabolic modulator which targets multiple pathways pivotal to metabolic regulation, including those associated with metabolic and digestive diseases. The Company conducts operations in the United States, Mainland China, Hong Kong and Australia.
Employees
51
Date Price Change Volume
31/07/26 HKD 2.600 +4.00% 44,000
30/07/26 HKD 2.500 -.--% 53,500
29/07/26 HKD 2.500 -3.10% 132,616
28/07/26 HKD 2.580 -2.64% 116,000
27/07/26 HKD 2.650 -.--% 25,000

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 2511 Stock